The Lys17 side chain is a C20 fatty diacid attached through a PEG2 spacer and a -glutamic acid linker
The SURMOUNT-3 trial, which added Tirzepatide after an intensive lifestyle lead-in, reported total weight reductions of up to 26.6%
Paddy Kalish OD, JD and B.Arch Author and Blogger You Might Also Enjoy
By improving overall metabolic health, reducing excess adiposity, and alleviating adipose tissue inflammation, tirzepatide could potentially mitigate upper airway collapsibility and ameliorate the underlying pathophysiological mechanisms of OSAS (27)
The multiple-dose regimen, given for up to 4 weeks, led to a dose-dependent weight loss between 2.87 and 5.46 kg, compared to 2.37 kg for placebo
Exposure to extreme temperatures, both hot and cold, puts the stability of benzyl alcohol at risk